Core Insights - Identifying value stocks requires a thorough analysis of key financial metrics such as earnings per share and sales growth to determine if a stock is undervalued [1] - The price-to-book (P/B) ratio is an important valuation tool that can help investors find low-priced stocks with high growth potential [2][6] Valuation Metrics - The P/B ratio is calculated as market capitalization divided by book value of equity, and a ratio less than one indicates that a stock is undervalued [2][6] - A P/B ratio greater than one suggests that a stock may be overvalued, while a ratio less than one could indicate weak returns or overstated assets [8][9] - Other important ratios to consider alongside P/B include price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity ratios for a comprehensive investment decision [10] Screening Parameters - Stocks with a P/B ratio lower than the industry median are considered to have potential for price appreciation [12] - A P/S ratio below the industry median indicates that the stock is attractively valued based on its sales [12] - A P/E ratio (F1) lower than the industry median is viewed favorably, as it suggests better valuation [13] - A PEG ratio of less than 1 indicates that a stock is undervalued relative to its growth prospects [14] - Stocks should have a current price of at least $5 and an average 20-day trading volume of 100,000 or more for liquidity [15] Notable Stocks - Centene Corporation (CNC) is a diversified healthcare company with a projected 3-5 year EPS growth rate of 11.5% and a Zacks Rank of 2 with a Value Score of A [16][17] - CVS Health Corporation (CVS) has a projected 3-5 year EPS growth rate of 11.4% and also holds a Zacks Rank of 2 with a Value Score of A [17] - Pfizer (PFE), a major pharmaceutical company, has a projected 3-5 year EPS growth rate of 9.0% and a Zacks Rank of 2 with a Value Score of A [18] - StoneCo (STNE), a financial technology provider, boasts a projected 3-5 year EPS growth rate of 26.3% and a Zacks Rank of 1 with a Value Score of B [19] - Paysafe Limited (PSFE) has a projected 3-5 year EPS growth rate of 17.9% and a Zacks Rank of 2 with a Value Score of A [21]

Core Insights - Centene (NYSE: CNC) presents a compelling investment opportunity with a low valuation, strong revenue and earnings growth, and a substantial membership base across the United States [1] Group 1 - The company is characterized by a bargain valuation, which may attract investors looking for undervalued stocks [1] - Centene has demonstrated healthy revenue and earnings growth, indicating robust financial performance [1] - The company boasts a large membership base, enhancing its market presence and potential for future growth [1]

Group 1: Earnings Season Overview - The 2025 Q1 earnings season is concluding, with most S&P 500 companies having reported results, which have been generally positive despite uncertainty from tariff discussions [1][19] Group 2: Netflix Performance - Netflix (NFLX) has seen a significant stock surge of 90% over the past year, attributed to strong results and reaffirmation of FY25 guidance [3][19] - Subscriber growth has been a key highlight, with only one quarter of negative growth in the last 12 quarters, and the introduction of ad-supported tiers has been successful [4][5] - The crackdown on password sharing has resulted in increased revenue opportunities, contributing to consistent double-digit percentage year-over-year sales growth for six consecutive periods [5] Group 3: Eaton Performance - Eaton (ETN) reported record Q1 adjusted EPS of $2.72 (up 13% YoY), record Q1 sales of $6.4 billion (up 7% YoY), and record segment margins of 23.9% (80 basis points increase YoY) [8] - Organic sales growth reached 9%, exceeding previous guidance, and backlog growth in the Electrical segment improved by 6% YoY, while Aerospace backlog surged by 16% [9] - The company has demonstrated a commitment to shareholder returns, with a 7% five-year annualized dividend growth rate [11] Group 4: Centene Performance - Centene (CNC) reported adjusted EPS of $2.90 and sales of $46.6 billion, exceeding consensus estimates with earnings up 28% YoY [13] - The company raised its 2025 premium and service revenues guidance by $6.0 billion due to higher-than-expected membership growth, reflecting a 17% YoY increase [13] - Analysts have adjusted sales expectations, with Centene now projected to achieve $179.6 billion in revenues for the current fiscal year [17]

Core Insights - Centene Corporation (CNC) benefits from a growing Medicaid membership, an aging U.S. population, contract wins, strategic acquisitions, and a strong financial position [1] Financial Performance - Centene currently holds a Zacks Rank 2 (Buy) and has seen its stock gain 7.3% over the past three months, contrasting with a 22.1% decline in the industry [2] - The Zacks Consensus Estimate for Centene's 2025 earnings is $7.27 per share, reflecting a year-over-year improvement of 1.5%, with revenues estimated at $179.6 billion, indicating a 10.2% increase [5] - The 2026 earnings estimate is $7.69 per share, showing a 5.7% increase from 2025, with revenues projected at $180 billion, a slight growth of 0.2% [5] - Centene's average earnings surprise over the last four quarters is 25.47%, with three out of four quarters exceeding estimates [7] Valuation Metrics - Centene's price-to-earnings (P/E) ratio stands at 11.17, compared to the multiline industry’s trailing 12-month P/E of 7.95, indicating that the stock is currently undervalued [8] Growth Drivers - Revenue growth is driven by an expanding Medicaid member base, which reached 27.9 million as of March 31, 2025, contributing to premium growth [9] - Premium and service revenues increased by 17% year-over-year in Q1 2025, with management projecting revenues between $164 billion and $166 billion for 2025, representing a 13.4% growth from 2024 [11] - Centene has secured Medicaid contract awards in Nevada, Arizona, and Illinois, and its Commercial Marketplace division serves 5.6 million members, a 29.4% year-over-year increase [11] Strategic Initiatives - The company actively engages in mergers and acquisitions to enhance capabilities and geographic reach while divesting non-core assets to focus on Managed Care operations [12] - Centene's financial stability is supported by a strong liquidity position, holding $14.8 billion in cash and cash equivalents as of March 31, 2025, a 5.3% increase from the end of 2024 [13]

Core Concept - The article emphasizes the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with potential for exceptional returns, alongside more commonly used ratios like price-to-earnings (P/E) and price-to-sales (P/S) [1][5]. P/B Ratio Overview - The P/B ratio is calculated by dividing the market price per share by the book value of equity per share, indicating how much investors are willing to pay for a share relative to its book value [1][5]. - A P/B ratio of less than one suggests that a stock is undervalued, while a ratio greater than one indicates it may be overvalued [5][6]. Book Value Definition - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities, calculated by subtracting total liabilities from total assets [3][4]. Limitations of P/B Ratio - The P/B ratio is particularly useful for industries with tangible assets, such as finance and manufacturing, but may be misleading for companies with high R&D expenses or significant debt [8][9]. Screening Parameters for Investment - Stocks with a P/B ratio lower than the industry median are considered to have potential for price appreciation [10]. - Additional screening criteria include lower P/S and P/E ratios compared to industry medians, a PEG ratio of less than 1, a current price of at least $5, and a minimum average trading volume of 100,000 [11][12][13]. Identified Low P/B Stocks - Centene Corporation (CNC) is highlighted as a diversified healthcare company with a projected 3-5 year EPS growth rate of 11.5% and a Zacks Rank of 2 [14][15]. - CVS Health (CVS) is noted for its integrated pharmacy care services, with a projected EPS growth rate of 11.4% and a Zacks Rank of 2 [15]. - Pfizer (PFE), a major pharmaceutical company, has a projected EPS growth rate of 9.0% and a Zacks Rank of 2 [16]. - StoneCo (STNE), a financial technology provider, boasts a high projected EPS growth rate of 26.3% and a Zacks Rank of 1 [17]. - Banco Santander (SAN), the largest bank in Spain, has a projected EPS growth rate of 8.6% and a Zacks Rank of 2 [18].

Wall Street saw a strong rally on Monday, driven by renewed optimism over U.S.-China trade relations. A 90-day agreement between the two nations to reduce tariffs has rekindled hopes of easing global trade tensions. The United States will lower duties on Chinese imports from a steep 145% to 30%, while China has agreed to cut its retaliatory tariffs on American goods from 125% to 10%, signaling a shift from confrontation to cooperation.Markets responded positively, with the S&P 500 jumping 3.3% to settle at ...

Industry Overview - The healthcare industry has faced challenges in early 2025, including concerns over potential cuts to Medicare and Medicaid, as well as the impact of tariffs on supplies [1] - Despite these challenges, healthcare stocks have performed relatively well, with the Health Care Select Sector SPDR Fund (XLV) down less than 2% year-to-date, compared to the S&P 500's decline of nearly 3% [1] Company Analysis: Centene - Centene Corp. (CNC) has shown solid membership and revenue growth, primarily driven by its Medicaid services, which have helped it withstand market volatility [3][4] - For Q1 2025, Centene reported a 29% year-over-year increase in Marketplace membership and a 22% increase in Medicare membership, contributing to a 28% improvement in adjusted diluted earnings per share (EPS) and a 17% growth in premium and service revenue [4] - The company has reiterated its full-year guidance, indicating optimism for future performance [4] Company Analysis: Tenet Healthcare - Tenet Healthcare Corp. (THC) has received positive analyst ratings, with 13 Buy ratings and four Holds, following a strong Q1 2025 earnings report that exceeded EPS estimates by $1.25 per share, reflecting a year-over-year improvement of over 35% [6][7] - The company plans to invest $250 million annually in its Ambulatory segment and has opened six new centers in Q1 2025, which are expected to drive continued growth [8] - Tenet's share repurchase program and efforts to improve its balance sheet are anticipated to enhance shareholder value [8] Company Analysis: Encompass Health - Encompass Health Corp. (EHC) reported better-than-expected earnings, leading to increased price targets from analysts [10] - The company's shares have risen over 25% year-to-date, with expectations of 10% projected earnings growth in the near term [11]

Group 1 - Adaptive Biotechnologies (ADPT) is outperforming its peers in the Medical sector, gaining about 47% year-to-date compared to the sector's average loss of 4.8% [4] - The Zacks Rank for Adaptive Biotechnologies is 2 (Buy), indicating a positive earnings outlook and strong analyst sentiment, with a 5.5% increase in the consensus estimate for full-year earnings [3][4] - The Medical group ranks 3 within the Zacks Sector Rank, which evaluates 16 different sector groups based on the average Zacks Rank of individual stocks [2] Group 2 - Adaptive Biotechnologies is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 8% this year, further highlighting ADPT's strong performance [6] - Another outperforming stock in the Medical sector is Centene (CNC), which has gained 3.9% year-to-date, with a Zacks Rank of 2 (Buy) and a 4.4% increase in the consensus EPS estimate [5][7] - The Medical - HMOs industry, where Centene belongs, has experienced a decline of 14% since the beginning of the year, contrasting with the performance of Adaptive Biotechnologies [7]

Centene (CNC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ch ...

Core Insights - Oklahoma Complete Health is enhancing its SoonerSelect benefits to improve health outcomes and overall well-being for its members [1][2] Benefit Enhancements - Introduction of a $30 per month Diaper Club for members aged 0-1 whose parents are enrolled in the Start Smart for Your Baby program or care management, starting July 1 [2] - Expansion of prescription limits where certain essential medicines will not count towards the 6-prescription monthly limit, aiding members who require more medications [3] - Over-the-Counter benefits will now provide a $30 allowance per member per quarter, allowing members to purchase items like cold medicines and vitamins [4] - Transportation benefits have been upgraded to allow up to 4 family members to accompany members to doctor's appointments, along with providing up to 15 rides for other essential trips [5] Member Engagement and Impact - In its first year, Oklahoma Complete Health completed over 11,651 referrals for social drivers of health needs, assisted more than 2,500 members with Food Rx benefits, facilitated over 20,684 YMCA visits, and distributed more than $2.1 million in reward dollars for healthy activities [6] - Member testimonials highlight the positive impact of the services provided, emphasizing support in accessing resources and maintaining communication [7] Organizational Overview - Oklahoma Complete Health is a care management organization focused on serving Oklahomans with various health insurance solutions and is a subsidiary of Centene Corporation [8][9]